| Document |
Document Title |
|
WO/2016/111140A1 |
A photoelectric conversion element wherein: at least one organic layer is present between a first electrode and a second electrode; and the organic layer contains at least two compounds in combination, said two compounds having the same ...
|
|
WO/2016/105485A2 |
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
|
|
WO/2016/102877A1 |
The invention relates to novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I), to pharmaceutical compositions containing said compounds, and to the use of said compounds and said compositions for the treat...
|
|
WO/2016/106334A2 |
Disclosed herein are compositions comprising blocked puromycin analogs that are converted into active puromycin analogs upon the activity of a penicillin acylase. Also disclosed are methods of using blocked puromycin analogs to label pro...
|
|
WO/2016/105448A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in ...
|
|
WO/2016/104317A1 |
The present invention addresses the problems of providing a polymerizable compound which, when added to a polymerizable composition, has high storage stability without causing any crystal precipitation, etc. and of providing a polymeriza...
|
|
WO/2016/102882A1 |
The invention relates to novel heterocyclic compounds of general formula (I), to the pharmaceutically acceptable salts thereof, and to the enantiomers of same. The invention also relates to the use thereof as as medicaments, preferably i...
|
|
WO/2016/097394A1 |
The invention relates to bicyclic sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan re...
|
|
WO/2016/096631A1 |
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.
|
|
WO/2016/097840A1 |
The invention relates to a novel product and more specifically a glycerol acetal or glycerol ketal ether-ester, to the methods for the production thereof, and to the use of same as a solvent, co-solvent, plasticiser, coalescing agent, su...
|
|
WO/2016/097989A1 |
The present invention relates to an improved as well as an industrially viable process for the preparation of 2'-deoxy-2',2'-difluorocytidine and its pharmaceutical acceptable acid salts thereof in high purity and acceptable yield by usi...
|
|
WO/2016/094729A1 |
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of G...
|
|
WO/2016/092327A1 |
Disclosed herein are a class of compounds useful in cell culture, in particular, the in vitro culture of stem cells. The compounds have been found to promote the survival and/or maintenance of stem cells in (or during) culture and/or thr...
|
|
WO/2016/078738A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2016/080791A1 |
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. By using a specific combination of a plurality of host materials of the present disclosure, it is possible to p...
|
|
WO/2016/065980A1 |
Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immuno...
|
|
WO/2016/061862A1 |
A technique for preparing an amorphous posaconazole. Posaconazole is dissolved in a mixed solvent of an alcohol and an ester, is added to an alkane, a cycloalkane, or an arene, and undergoes precipitation so as to separate out jelly-like...
|
|
WO/2016/062791A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer...
|
|
WO/2016/065264A1 |
Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/ NF-κΒ pathways....
|
|
WO/2016/051368A1 |
The present disclosure relates to solid dispersion of a complex of amorphous empagliflozin and a cyclodextrin.
|
|
WO/2016/045769A1 |
The invention relates to heterocyclic compounds with benzo[c]coumarin structures and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2016/047924A2 |
The present invention relates to a fluorescent-labeled novel dieckol derivative.
|
|
WO/2016/044770A1 |
Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. P...
|
|
WO/2015/140717A9 |
The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also...
|
|
WO/2016/038624A1 |
The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying ...
|
|
WO/2016/038583A1 |
The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provid...
|
|
WO/2016/040554A1 |
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
|
|
WO/2016/036171A1 |
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. By comprising a specific combination of a plurality of host materials, the organic electroluminescent device of...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/031605A1 |
The present invention solves various problems associated with conventional external preparations used for ameliorating skin diseases which have been issues of concern. The purpose of the present invention is to provide an external prepar...
|
|
WO/2016/030534A1 |
The present disclosure discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders assoc...
|
|
WO/2016/020615A1 |
The invention concerns a compound of general formula (I) in which R1, R2, R3 and R5, identical or different, each represent a hydrogen atom or a hydroxyl group, optionally protected by a protecting group; R4 represents a hydrogen atom or...
|
|
WO/2016/017466A1 |
Provided is a noxious arthropod control agent containing an amide compound represented by formula (I) [In the formula, X represents a nitrogen atom or CH group, p represents 0 or 1, A represents a tetrahydrofuranyl group or the like, R1,...
|
|
WO/2016/009296A1 |
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trkantagonists.
|
|
WO/2016/005878A1 |
Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds (Formula I)
|
|
WO/2016/002853A1 |
The purpose of the present invention is to provide a novel compound that is capable of activating glycogen synthase but hardly activates receptor PPAR and shows high safety. Provided is a compound represented by general formula (I) or a ...
|
|
WO/2016/003158A2 |
The present invention relates to a new compound for inhibiting binding between a DX2 protein and a p14/ARF protein, and a medical use thereof. A review of the in vitro and in vivo anticancer effect of the compound shows that the compound...
|
|
WO/2015/192198A1 |
A method is described for treating a peroxisome biogenesis disorder by administering to an individual in need thereof an effective amount of an autophagy inhibitor. Uses, compositions, and commercial packages are also described. The pero...
|
|
WO/2015/191752A1 |
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A', R1, R2, and R3 are described herein. The compounds are inhibitors to th...
|
|
WO/2015/190489A1 |
The purpose of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention pertains to a compound represented by general formula (IA): (the symbols in the formula are as stated in the s...
|
|
WO/2015/188073A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2015/182686A1 |
The present invention addresses the problem of providing a medicinal composition and, in particular, a compound suitable for treating nocturia. Under the expectation that nocturnal urinary frequency could be reduced via an antidiuretic a...
|
|
WO/2015/181470A1 |
The invention relates mainly to a method for producing a composition of glycidyl ethers synthesised from furan derivatives (furan glycidyl ethers), partly characterised by azeotropic distillation performed under reduced pressure and with...
|
|
WO/2015/177083A1 |
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...
|
|
WO/2015/174695A1 |
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...
|
|
WO/2015/169854A1 |
The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or ...
|
|
WO/2015/169412A1 |
The invention relates to carbazole, dibenzofurane, dibenzothiophene and fluorene derivatives which are substituted with electron-deficient heteroaryl groups, in particular for use as triplet matrix materials in organic light emitting dev...
|
|
WO/2015/167199A1 |
The present invention relates to an electron transport material and an organic electroluminescent device comprising the material in an electron transport layer. Tthe compounds according to the present invention as an organic electron tra...
|
|
WO/2015/160772A1 |
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, X, Z1and Z2 are defined in the specification.
|
|
WO/2015/158908A1 |
The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).
|
